Mortality in patients with end-stage renal disease (ESRD) remains unacceptably high. Emerging techniques and advances in dialysis technology have the potential to improve clinical outcomes in the ESRD population. This report summarizes the deliberations and recommendations of a conference sponsored by Kidney Disease: Improving Global Outcomes to address the following questions: (1) what is the appropriate frequency and duration of hemodialysis; (2) how should we optimize water quality and dialysate composition; and (3) what technical innovations in blood purification and bioengineering can result in better clinical outcomes? The conference report will augment our current understanding of clinical practice in blood purification and will pose several high-priority research questions.
Bibliographical noteFunding Information:
This conference was sponsored by Kidney Disease: Improving Global Outcomes and was partially supported by educational grants from Baxter, Fresenius, Gambro, and Takeda/Affymax.
AC has received honoraria from Amgen, FMC, Abbott, and Roche. MKK has received speaker honoraria from Abbott, Baxter, Gambro, Genzyme, Fresenius, Sanofi-Aventis, and Shire. CTC is a member of the Baxter Scientific Advisory Board. MVR is a consultant for DaVita and Amgen. PKTL received speaker honoraria from Baxter, FMC, and Roche, and is a member of Baxter Trial Advisory Board. NWL owns Fresenius stock and has served on Affymax and Roche Advisory Boards. DCW has received honoraria from Amgen, FMC, Abbott, and Shire, and research funding from Abbott, Roche, and Genzyme. All the other authors declared no competing interests.
- blood purification
- daily hemodialysis
- intensive hemodialysis
- nocturnal hemodialysis